Home LiteratureArticle Details
PMID: 3770038 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Tissue distribution and myelotoxicity of daunomycin in the rat: rapid bolus injection vs continuous infusion.

European journal of cancer & clinical oncology ·Vol. 22 ·No. 7 ·1986-07-00 ·Pages 801-6

Nooter K, Sonneveld P, Martens A, Hagenbeek A, Schultz F

Abstract

The pharmacokinetic and cytotoxic behaviour of daunomycin in rats (7.5 mg/kg) when administered as an i.v. bolus injection were compared with those of a 3-hr infusion. After an i.v. bolus injection, the plasma drug levels decreased triphasically (t1/2 alpha = 0.8 min, t1/2 beta = 29.6 min and t1/2 gamma = 9.9 hr). The organs showed two types of concentration/time curves. One was found in the lungs, liver, kidneys and heart and had an initial high drug concentration followed by a relatively rapid elimination. The other was shown by the hemopoietic tissues (spleen and bone marrow): the drug uptake phase lasted longer (about 1.5 hr) and the elimination was slower. In general, daunomycin infusion led to substantially lower plasma and tissue levels, including in the heart, liver and kidneys. Again the hemopoietic tissues behaved in a different way: in spleen and bone marrow almost equal drug levels were obtained after daunomycin infusion as compared to a bolus injection. The myelotoxicity after daunomycin treatment was assessed by CFU-S (colony forming units-spleen) survival: the bolus injection killed as many CFU-S as did infusion (mean +/- S.D.: 11.8 +/- 5.3 CFU-S survival versus mean +/- S.D.: 13.5 +/- 2.4). Thus, it can be predicted that daunomycin infusion will lead to less cardiotoxicity but to an equal bone marrow suppression.

MeSH Terms
Animals Bone Marrow/drug effects Cell Survival/drug effects Colony-Forming Units Assay Daunorubicin/administration & dosage,analogs & derivatives,metabolism,pharmacology Female Infusions, Intravenous Injections, Intravenous Rats Time Factors Tissue Distribution
Chemicals
daunorubicinol Daunorubicin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Nooter K
Sonneveld P
Martens A
Hagenbeek A
Schultz F
Article Info
Journal
European journal of cancer & clinical oncology
Abbr.
Eur J Cancer Clin Oncol
ISSN
0277-5379
Published
1986-07-00
Pages
801-6
Language
English
Region
England
NLM ID
8112045
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com